Aspirin MI Primary Prevention Labeling Urged In Bayer Citizen Petition
This article was originally published in The Tan Sheet
Executive Summary
Aspirin therapy led to a statistically significant 32% reduction in first myocardial infarctions among over 55,000 subjects evaluated in a meta-analysis of five primary prevention studies conducted by Bayer Consumer Care
You may also be interested in...
Aspirin Tops Three Rx Drugs In Preventing Heart Attack – Consumers Union
Aspirin is the blood thinning agent of choice over three prescription antiplatelet medications for preventing first or repeat heart attack or stroke, according to a Consumers Union report
Aspirin Use For CVD Prevention Low Among At-Risk Patients – Study
A survey on aspirin use for cardiovascular disease prevention shows low usage "even among patients at increased risk" and could encourage FDA to act on a Bayer's 2003 citizen petition to include a primary prevention indication in professional labeling for aspirin, a researcher says
CHARISMA May Make Bayer Primary MI Prevention Petition More Popular
Bayer's bid for an indication for the primary prevention of MI on professional aspirin labeling may be strengthened by data from the CHARISMA trial